Opioid Overdose and Naloxone: Reversing the Respiratory Brake

The mechanism of toxicity: silencing the brainstem

Opioids don't damage the lungs — they switch off the drive that runs them. Every opioid — heroin, morphine, oxycodone, fentanyl — works by stimulating the mu-opioid receptor. In the right dose that brings analgesia; in overdose it brings a cascade of central depression. The receptors that matter most sit in the brainstem, in the respiratory centres that set the rhythm and depth of breathing and that normally respond to rising carbon dioxide by making you breathe harder. Flood those receptors and that reflex is blunted: carbon dioxide climbs, oxygen falls, and the patient simply doesn't feel the urge to breathe. Respiratory depression — slow, shallow, and eventually absent breathing — is the mechanism of death. Everything else the opioid does is a bystander sign. This receptor pharmacology is developed fully in the Central Nervous System section, under opioid analgesics and their agonists and antagonists.

The classic triad — and why the pupils are the least important part

The opioid toxidrome is taught as a triad: depressed consciousness, respiratory depression, and pinpoint pupils (miosis). The miosis is the most famous sign — pupils constricted to pinheads because mu activation drives the pupil-constricting fibres — and it is the one students latch onto. But it is diagnostically seductive and clinically trivial. Pinpoint pupils never harmed anyone; they are a marker, not a threat. The number that decides whether the patient lives is the respiratory rate. A patient breathing four times a minute with normal-sized pupils is in far more danger than one breathing sixteen times a minute with tiny ones. Treat the breathing, not the pupils. The full catalogue of toxidromes — cholinergic, anticholinergic, sympathomimetic, sedative — is compared side by side in the Toxidromes chapter; the opioid picture is the one that most cleanly maps a receptor to a bedside sign.

The triad is reliable — until it isn't. Two important exceptions break the pattern, and both are exam favourites. First, not every opioid causes miosis. Meperidine (pethidine) and, above all, tramadol have extra pharmacology beyond the mu receptor: they inhibit serotonin and noradrenaline reuptake and lower the seizure threshold, so their overdoses can present with seizures, agitation, and even a serotonin syndrome rather than the placid pinpoint picture. Second, real overdoses are rarely pure. A patient who has also taken a stimulant like cocaine, or a drug that dilates pupils, may show mid-sized or normal pupils despite genuine opioid respiratory depression. So the absence of miosis never rules out opioid toxicity — if the patient is not breathing, treat as opioid poisoning regardless of the pupils.

The antidote: naloxone, a competitive mu antagonist

Naloxone doesn't do anything itself — it evicts the opioid from the receptor. Naloxone is a pure, competitive antagonist at the mu-opioid receptor. It has no opioid effect of its own; it simply binds the receptor more avidly than the opioid and knocks it off, lifting the block on the respiratory centre. Give it to a patient who has stopped breathing from heroin and, within a minute or two, the respiratory drive returns and the patient breathes. It is one of the most dramatic and satisfying interventions in all of medicine — a genuine, mechanism-clean reversal. Because it is a competitive antagonist, its effect is dose-dependent and surmountable: a large opioid load can be overcome with more naloxone, which matters enormously for the ultra-potent synthetics discussed below. Naloxone is also the opioid limb of the traditional "coma cocktail" — the reflex bedside package of oxygen, glucose (dextrose), thiamine, and naloxone once given empirically to any unresponsive patient — which is set out in the Approach to the poisoned patient chapter.

The dosing principle: titrate to breathing, not to alertness

Here is the single most important rule of using naloxone, and the one exams test relentlessly. The goal is to restore adequate ventilation — a patient breathing well enough to oxygenate — NOT to produce a fully awake, alert patient. Over-reversal is a real harm, not a bonus. Slam a large dose into a physically dependent patient and you strip every opioid off every receptor at once, precipitating acute opioid withdrawal: sudden agitation, sweating, vomiting, diarrhoea, and a distressed, combative patient who may pull out lines and refuse care. Worse, abrupt over-reversal has been linked to a surge of catecholamines and, in some cases, flash (acute) pulmonary oedema. So the technique is deliberate: start with a small dose, give oxygen and support ventilation, and titrate upward in small increments until the patient is breathing adequately — then stop. You are aiming for a safely breathing patient, not a bright-eyed one.

The antidote is short-lived; many opioids are not. Naloxone has a short duration of action — often shorter than the opioid it is reversing. This is the trap that catches the unwary. Reverse a patient with a long-acting opioid such as methadone, or a modified-release oral preparation, or a transdermal fentanyl patch, and the naloxone can wear off while a large depot of opioid is still being absorbed — the patient re-sedates and stops breathing again, sometimes an hour or two after apparently waking. The safe response is never to reverse-and-discharge: observe the patient for an adequate period, and for long-acting agents give repeated doses or a continuous naloxone infusion titrated to breathing. A patient who woke to a single dose of naloxone is not "cured" — they are borrowing time, and the clock is short.

Routes, take-home naloxone, and special situations

Naloxone is flexible in how it is given. In hospital the intravenous route allows the finest titration, but it also works intramuscularly, and — importantly for the community — intranasally. That intranasal formulation is the basis of take-home naloxone: kits handed to people who use opioids, and to their families and friends, so that a bystander can reverse an overdose in the crucial minutes before an ambulance arrives. It is one of the most effective harm-reduction measures in modern public health, and it turns the antidote from a hospital drug into something that saves lives at the scene. Note that take-home naloxone is emergency first aid, not definitive care: the same short-half-life caveat applies, so every use should still be followed by a call for medical help.

Three modern scenarios stretch the standard playbook. First, fentanyl and its ultra-potent analogues (carfentanil and others) now dominate overdose deaths in many regions. Because they bind the mu receptor so tightly and in such tiny quantities, reversing them often needs repeated or larger doses of naloxone — a single small dose may not be enough, exactly the surmountable-competition principle in action. Second, the body-packer: someone who has swallowed or concealed sealed packets of opioid to smuggle them. If a packet leaks or ruptures, they can develop massive, prolonged overdose from a huge internal reservoir — these patients need infusions and careful surgical/medical decisions, not a single dose. Third, the opioid-tolerant patient (someone on long-term opioids for pain, or on maintenance therapy) needs especially gentle titration, because a full-reversal dose will throw them into severe, avoidable withdrawal.